Losartas 100mg (Source: HSA).

The Health Sciences Authority (HSA) has recalled Hyperten Tablet, Losagen Tablet, and Losartas Tablet from Hetero Labs Ltd as they were found to contain trace amounts of a nitrosamine impurity, N-nitroso-N-methyl-4-aminobutyric acid (NMBA), which are above internationally acceptable levels.

In its press release, HSA advised patients not to stop treatment on their own as there is no immediate health risk associated with taking the affected medicines. However, healthcare professionals are encouraged to review the medicine and treatment plans of their patients.

In a separate press release, the Ministry of Health (MOH) stated that about 137,000 patients in Singapore are using the three recalled brands of losartan medicine. Of these, about 130,000 patients have been prescribed Losartas at public healthcare institutions.

The authority noted that not all losartan medicines are affected by this recall, saying that only three out of the ten losartan products in Singapore contain unacceptable levels of nitrosamine impurity.

Hyperten 50mg (Source: HSA).
Hyperten 100mg (Source: HSA).
Losagen 50mg (Source: HSA).
Losagen 100mg (Source: HSA).
Losartas 100mg (Source: HSA).
Losartas 50mg (Source: HSA).

According to the authority, losartan belongs to a class of medicines called angiotensin II receptor blockers (ARBs), which are used to treat high blood pressure, also known as hypertension.

In addition to the three recalled brands, there are seven other brands of losartan medicines marketed in Singapore and these seven brands have been tested by HSA and do not contain NMBA:

The authority stated that since June 2018, several ARB medicines have been recalled overseas due to the presence of two other nitrosamine impurities, N-Nitrosodimethylamine (NDMA) and N-Nitrosodiethylamine (NDEA).

HSA noted that it had tested the locally marketed ARB medicines and none of them was found to contain unacceptable levels of the two impurities.

In end-June 2018, several valsartan-containing medicines were recalled overseas due to the presence of NDMA. Based on HSA’s checks, none of valsartan products marketed in Singapore were affected.

Meanwhile, in September 2018, several overseas regulatory agencies recalled affected ARBs due to the presence of NDEA. HSA had tested the ARBs marketed in Singapore and none were found to contain unacceptable levels of these impurities.

Since November 2018, HSA stressed that it has required companies to test for these impurities in their products and comply with international standards, to ensure the continued quality of the products imported into Singapore.

Since end-February 2019, several losartan medicines were recalled overseas due to the presence of NMBA.

According to the authority, all locally marketed losartan products have been tested for the presence of the new NMBA impurity. By testing all brands of losartan medicines available locally beyond Hetero Labs products, HSA said that it is able to advise which brands did not contain NMBA, and help healthcare professionals decide on suitable alternatives for patients in place of the recalled brands.

HSA said that the risks of trace amounts of NMBA are associated with long term exposure. Sudden stopping of the medicines can pose a greater and more immediate risk to the patient’s health.

Professor Ding Zee Pin, Cardiologist in the National Heart Centre Singapore and HSA’s Expert Panel on Nitrosamines advises: “There is no immediate health risk associated with taking the affected medicines, and patients are advised not to stop or change treatment on their own. As losartan is used to treat high blood pressure, stopping the medicine without replacement of other equivalent medication can increase the risk of poor control of blood pressure.”

HSA advises consumers who are taking the three affected brands of losartan medicines to do the following:

  • Do not stop taking the medicines on your own until you have been provided with a replacement brand of losartan or a different medicine by your healthcare provider.
  • Discuss your medication and treatment plan with your healthcare provider.  Your healthcare provider has been advised to make arrangements to review and provide you with alternatives or other therapies.
  • Only three of the ten losartan products in Singapore – Hyperten, Losagen and Losartas – contain the nitrosamine impurity. Consult your healthcare provider if you are unsure if you are taking an affected brand.
  • Consumers can contact the HSA hotline at Tel: 6866 3538 or email: [email protected] if you have further enquiries.
Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments
You May Also Like

Nine tobacco retail licences suspended for selling tobacco products to minors under 18 years of age

Health Sciences Authority (HSA) has suspended the tobacco retail licences of nine…

【选举】“清除障碍”决策未来 李显龙:此时是大选最佳时期

李显龙总理表示,他今早向哈莉玛总统建议解散国会,因为他认为现在正是大选的最佳时期,能够清除障碍,让新政府能够在未来的五年任期内,集中于恢复国家经济等领域的议程,以及做出艰难的决定。 李总理在全国演说后,于脸书帖文指出,他今早向总统建议解散国会并颁布选举令状,并于6月30日进行候选人提名,而7月10日进行大选投票。 他指出,冠状病毒19之后的复苏工作,将使我国的最大考验之一,因此国民上下必须团结一致。“在当前相对稳定的情况下举办国家选举,将能够清除障碍,赋予政府新的五年任期。然后,我们将能够专注于复苏的议程,并在必须的时候做出艰难决定。” 帖文中,他表示了解民众会担忧疫情复发,对此,选举局将在投票日当天实施一些额外措施,包括增加投票站以减少人潮拥挤的机会、提供选民特定的投票时间、并且给予年长者投票优先权。 “此次的选举将和以往的有所不同,不仅因为疫情,其中还涉及了重大课题。” 他指出,新政府将有责任做出足以影响人民未来生计的决定,甚至会影响国家的未来许多年。“我相信你们会认真思考后明智投票,以确保我们的生活、工作和未来。”

Malaysia refuses to host any events involving Israeli participants, says Foreign Minister Saifuddin Abdullah; discreet economic relations with Israel “booming” despite Malaysia’s diplomatic hostility?

Following the announcement by Prime Minister Dr Mahathir Mohamad regarding the ban…

Starbucks latest target of Hong Kong protestors following condemnation by daughter of Maxim's Caterers founder

Starbucks has emerged as the latest brand to fall foul of Hong…